Home » Topics » BioWorld Science

BioWorld Science
RSS

MJFF grant supports Neuropore's development of TLR2 antagonist for Parkinson's disease

April 20, 2022

TAK-676 shows antitumor efficacy as monotherapy or in combination

April 20, 2022

Ono establishes collaborations to discover small molecules targeting GPCRs in metabolic disease

April 20, 2022

Shanghai Visonpharma synthesizes new TLR7 agonists

April 20, 2022

New P2X3 antagonists presented by National Institute of Pharmaceutical R&D

April 20, 2022

Medshine Discovery identifies new CSF-1R inhibitors

April 20, 2022

CSPC Zhongqi Pharmaceutical Technology divulges salts of tyrosine kinase inhibitors

April 20, 2022

Guangzhou Fermion Technology patents new CDK7 inhibitors

April 20, 2022

Plexium compound shows the promise of BRD4 degradation for prostate cancer

April 20, 2022

TLR2/6 agonist AXA-042 shows antitumor activity and tolerability in vivo

April 20, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.